VanEck Pharmaceutical ETF PPH
118.83 USD -0.20 (-0.17%)
At closeNov 6, 2026, 4:00 PM EST
118.83 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
116.48 Day range 119.59
93.89 52-week range 122.11
- YTD
- +15.18%
- 1 year
- +26.01%
News
benzinga.com Two Years to Build or Pay 200% — Which US Pharma Stocks Win? Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
benzinga.com Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery Bristol Myers Squibb expands AI efforts through Anthropic and Tempus partnerships as shares edge higher Wednesday.
benzinga.com What's Going On With Merck Stock Tuesday? Merck begins tender offer for Terns at $53 per share as part of its planned acquisition announced in March 2026.
benzinga.com Biotech ETF With A Twist: Defiance To Donate Initial Advisory Profits To Autism Causes Ahead of April, also the autism acceptance month, Defiance filed for a biopharma ETF with a pledge to donate profits to autism services and research.
benzinga.com Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery Merck teams up with Mayo Clinic to use AI for drug discovery, focusing on inflammatory diseases and more.
benzinga.com Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
benzinga.com Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus Novo Nordisk's FDA-approved weight-loss pill intensifies its rivalry with Eli Lilly, putting health care and biotech ETFs in focus.
benzinga.com Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
benzinga.com Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.
benzinga.com Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.
benzinga.com Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
benzinga.com Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
benzinga.com Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
benzinga.com Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
benzinga.com Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
benzinga.com Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
benzinga.com Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
benzinga.com Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
benzinga.com Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
benzinga.com Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
benzinga.com Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
benzinga.com New Study Suggests Drug Prices Have Doubled Since 2011: What's It Mean For The Market? 
benzinga.com 4 Health Care ETFs Your Broker Forgot to Mention 
benzinga.com More Pain Awaits Medical Device ETFs 
benzinga.com 10 ETFs That Should Lower Their Expense Ratios 
benzinga.com Fifteen Health Care ETFs Trading Near 52-Week Highs 
benzinga.com ETFs To Watch July 30, 2010 (HAO, PPH, YCS, PALL) 
benzinga.com ETFs To Watch April 20, 2010 (PPH, XLK, KOL, ROB)